What's in Santen SAS's pipeline?

Santen SAS has 12 drugs in our index: 1 marketed, 0 filed, 8 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with Santen SAS's portfolio?

Top competitors by shared drug class: Berinstein, Jeffrey, GlaxoSmithKline, Assistance Publique - Hôpitaux de Paris, Bausch Health Americas, Inc., CCTU.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/santen-sas.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Santen SAS — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Santen SAS pipeline: 1 marketed, 0 filed, 8 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 8 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
NOVA63035 "Corticosteroid"	NOVA63035 "Corticosteroid"	marketed	Corticosteroid	Glucocorticoid receptor	Ophthalmology or Dermatology
Masked Ikervis	Masked Ikervis	phase 3	Calcineurin inhibitor (ophthalmic)	Calcineurin	Ophthalmology
NOVA22007 ''Ciclosporin''	NOVA22007 ''Ciclosporin''	phase 3	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)	Immunology
Xalatan®/DE-130A	Xalatan®/DE-130A	phase 3	prostaglandin analogue	FP receptor	Ophthalmology
NOVA22007 (Ciclosporin 0.1%)	NOVA22007 (Ciclosporin 0.1%)	phase 3	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)	Ophthalmology
DE-130A/DE-130A	DE-130A/DE-130A	phase 3	Prostaglandin analog or intraocular pressure-lowering agent		Ophthalmology
NOVA22007	NOVA22007	phase 3	NK1 receptor antagonist	NK1 receptor (neurokinin-1 receptor)	Ophthalmology
DE-130A	DE-130A	phase 3			Ophthalmology
Open-label Ikervis	Open-label Ikervis	phase 3	Immunosuppressant (topical ophthalmic)	Calcineurin (via cyclosporine binding to cyclophilin)	Ophthalmology

Therapeutic area mix

Ophthalmology · 8
Immunology · 1
Ophthalmology or Dermatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Berinstein, Jeffrey · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Bausch Health Americas, Inc. · 2 shared drug classes
CCTU · 2 shared drug classes
Chinese PLA General Hospital · 2 shared drug classes
Allergan · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Santen SAS:

Cite this brief

Drug Landscape (2026). Santen SAS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/santen-sas. Accessed 2026-06-10.